News 09.09.2019 Schlieren (Zurich), 9 September 2019 - LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Kenya of a 4-valent candidate vaccine to help prevent diarrheal disease caused by the Shigella bacteria in children and infants in low and middle-income regions. This study is conducted in...
News 03.09.2019 Schlieren (Zurich), Switzerland, September 3, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial to evaluate the use of Fibrin-PTH (KUR-113) in...
News 27.08.2019 Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA approval; MP0250 in...
News 20.08.2019 Schlieren (Zurich), Switzerland, August 20, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2019. The Company accelerated product sales in the first half of 2019, while further decreasing administrative expenses, confirming its successful transition into a full-fledged...
News 25.07.2019 Zurich, Switzerland and Rockville, MD, July 24, 2019 -- Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics and REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV®...